Trefoil peptides as proangiogenic factors in vivo and in vitro: Implication of cyclooxygenase-2 and EGF receptor signaling

FASEB Journal

Volumn 17, Issue 1, 2003, Pages 7-16

  Rodrigues, Sylvie ^e   Van Aken, Elisabeth ^a   Van Bocxlaer, Saskia ^a   Attoub, Samir ^d   Nguyen, Quang Dé ^d   Bruyneel, Erik ^a   Westley, Bruce R ^b   May, Felicity E B ^b   Thim, Lars ^c   Mareel, Marc ^a   Gespach, Christian ^d   Emami, Shahin ^d  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c NOVO NORDISK A S   (Denmark)

^d HÔPITAL SAINT ANTOINE   (France)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; LEPTIN; MATRIGEL; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; PROTEIN PS2; THROMBOXANE A2 RECEPTOR; TRANSFORMING GROWTH FACTOR ALPHA; TREFOIL PEPTIDE; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; ASSAY; CANCER CELL; CANCER GROWTH; CELL INVASION; CELL TRANSPORT; CHORIOALLANTOIS; COLON CANCER; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; KIDNEY CANCER; MORPHOGENESIS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN FUNCTION; RECEPTOR BINDING; SIGNAL TRANSDUCTION; SOLID TUMOR; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; WOUND HEALING;

ANIMALIA; LOTUS;

EID: 0037245246     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.02-0201com     Document Type: Article

References (76)

1. André, T., Kotelevets, L., Vaillant, J. C., Coudray, A. M., Weber, L., Prevot, S., Parc, R., Gespach, C., Chastre, E. (2000) Vegf, Vegf-B, Vegf-C and their receptors KDR, FLT-1 and FLT-4 during the neoplastic progression of human colonic mucosa. Int. J. Cancer 86, 174-181
2. Podolsky, D. K. (1991) Inflammatory bowel disease (1). N. Engl. J. Med. 325, 928-937
3. i2-deficient mice. Nat. Genet. 10, 143-150
4. Okada, F., Kawaguchi, T., Habelhah, H., Kobayashi, T., Tazawa, H., Takeichi, N., Kitagawa, T., Hosokawa, M. (2000) Conversion of human colonic adenoma cells to adenocarcinoma cells through inflammation in nude mice. Lab. Invest. 80, 1617-1628
5. Folkman, J., Shing, Y. (1992) Angiogenesis. J. Biol. Chem. 267, 10931-10934
6. Carmeliet, P., Jain, R. K. (2000) Angiogenesis in cancer and other diseases. Nature (London) 407, 249-257
7. Lyden, D., Hattori, K., Dias, S., Costa, C., Blaikie, P., Butros, L., Chadburn, A., Heissig, B., Marks, W., Witte, L., et al. (2001) Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 7, 1194-1201
8. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31
9. Hanahan, D., Folkman, J. (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364
10. Shweiki, D., Itin, A., Soffer, D., Keshet, E. (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature (London) 359, 843-845
11. Kung, A. L., Wang, S., Klco, J. M., Kaelin, W. G., Livingston, D. M. (2000) Suppression of tumor growth through disruption of hypoxia-inducible transcription. Nat. Med. 6, 1335-1340
12. Fidler, I. J., Ellis, L. M. (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79, 185-188
13. Ferrara, N., Alitalo, K. (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359-1364
14. Vinals, F., Pouyssegur, J. (2001) Transforming growth factor beta1 (TGF-beta1) promotes endothelial cell survival during in vitro angiogenesis via an autocrine mechanism implicating TGF-alpha signaling. Mol. Cell. Biol. 21, 7218-7230
15. Gupta, R. A., DuBois, R. N. (2001) Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 1, 11-21
16. Hoffmann, W., Jagla, W., Wiede, A. (2001) Molecular medicine of TFF-peptides: from gut to brain. Histol. Histopathol. 16, 319-334
17. Emami, S., Le Floch, N., Bruyneel, E., Thim, L., May, F., Westley, B., Rio, M. C., Mareel, M., Gespach, C. (2001) Induction of scattering and cellular invasion by trefoil peptides in src- and RhoA-transformed kidney and colonic epithelial cells. FASEB J. 15, 351-361
18. Tran, C. P., Cook, G. A., Yeomans, N. D., Thim, L., Giraud, A. S. (1999) Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. Gut 44, 636-642
19. Rodrigues, S., Nguyen, Q. D., Faivre, S., Bruyneel, E., Thim, L., Westley, B., May, F., Flatau, G., Mareel, M., Gespach, C., et al. (2001) Activation of cellular invasion by trefoil peptides and src is mediated by cyclooxygenase- and thromboxane A2 receptor-dependent signaling pathways. FASEB J. 15, 1517-1528
20. Régnauld, K., Nguyen, Q. D., Vakaet, L., Bruyneel, E., Launay, J. M., Endo, T., Mareel, M., Gespach, C., Emami, S. (2002) G-protein αolf subunit promotes cellular invasion, survival, and neuroendocrine differentiation in digestive and urogenital epithelial cells. Oncogene 21, 4020-4031
21. Prest, S. J., May, F. E., Westley, B. R. (2002) The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J. 16, 592-594
22. Bossenmeyer-Pourie, C., Kannan, R., Ribieras, S., Wendling, C., Stoll, I., Thim, L., Tomasetto, C., Rio, M. C. (2002) The trefoil factor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J. Cell Biol. 157, 761-770
23. Liu, D., El-Hariry, I., Karayiannakis, A. J., Wilding, J., Chinery, R., Kmiot, W., McCrea, P. D., Gullick, W. J., Pignatelli, M. (1997) Phosphorylation of β-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab. Invest. 77, 557-563
24. Rio, M. C., Bellocq, J. P., Daniel, J. Y., Tomasetto, C., Lathe, R., Chenard, M. P., Batzenschlager, A., Chambon, P. (1988) Breast cancer-associated pS2 protein: Synthesis and secretion by normal stomach mucosa. Science 241, 705-708
25. Bonkhoff, H., Stein, U., Welter, C., Remberger, K. (1995) Differential expression of the pS2 protein in human prostate and prostate cancer: association with premalignant changes and neuroendocrine differentiation. Hum. Pathol. 26, 824-828
26. Machado, J. C., Nogueira, A. M., Carneiro, F., Reis, C. A., Sobrinho-Simoes, M. (2000) Gastric carcinoma exhibits distinct types of cell differentiation: an immunohistochemical study of trefoil peptides (TFF1 and TFF2) and mucins (MUC1, MUC2, MUC5AC, and MUC6). J. Pathol. 190, 437-443
27. Wang, D. G., Johnston, C. F., Liu, W. H., Sloan, J. M., Buchanan, K. D. (1997) Expression of a breast-cancer-associated protein (pS2) in human neuroendocrine tumours. Int. J. Cancer 74, 270-274
28. Colombel, M., Dante, R., Bouvier, R., Ribieras, S., Pangaud, C., Maréchal, J. M., Lasne, Y. (1999) Differential RNA expression of the pS2 gene in the human begnin and malignant prostatic tissue. J. Urol. 162, 927-930
29. Nunez, A. M., Berry, M., Imler, J. L., Chambon, P. (1989) The 5′flanking region of the pS2 gene contains a complex enhancer region responsive to œstrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J. 8, 823-829
30. Taupin, D., Wu, D. C., Jeon, W. K., Devaney, K., Wang, T. C., Podolsky, D. K. (1999) The trefoil gene family are coordinately expressed immediate-early genes: EGF receptor- and MAP kinase-dependent interregulation. J. Clin. Invest. 103, R31-R38
31. Sierra-Honigmann, M. R., Nath, A. K., Murakami, C., Garcia-Cardena, G., Papapetropoulos, A., Sessa, W. C., Madge, L. A., Schechner, J. S., Schawbb, M. B., Polverini, P. J., et al. (1998) Biological action of leptin as an angiogenic factor. Science 281, 1683-1686
32. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Pomatico, G., De Placido, S., Bianco, A. R., Tortora, G. (2000) Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. 6, 2053-2063
33. Rodrigues, S., Bruyneel, E., Nguyen, Q. D., Tournigand, C., Mareel, M., Emami, S., Gespach, C. (2001) Suppression of cellular invasion induced by the trefoil factor pS2, leptin, and the src oncogene by the epidermal growth factor receptor (EGF-R) tyrosine kinase inhibitor Iressa (ZD1839) and a dominant negative form of the EGF-R. Clin. Cancer Res. 7, Suppl. 3771S (abstr. 584)
34. Passaniti, A., Taylor, R. M., Pili, R., Guo, Y., Long, P. V., Haney, J. A., Pauly, R. R., Grant, D. S., Martin, G. R. (1992) A simple, quantitative method for assessing angiogenesis and antiangiogenic agents using reconstituted basement membrane, heparin, and fibroblast growth factor. Lab. Invest. 67, 519-528
35. Maragoudakis, M. E., Panoutsacopoulou, M., Sarmonika, M. (1988) Rate of basement membrane biosynthesis as an index to angiogenesis. Tissue Cell 20, 531-539
36. Liekens, S., Neyts, J., De Clercq, E., Verbeken, E., Ribatti, D., Presta, M. (2001) Inhibition of fibroblast growth factor-2 induced vascular tumor formation by the acyclic nucleoside phosphonate cidofovir. Cancer Res. 61, 5057-5064
37. Harris-Hooker, S. A., Gajdusek, C. M., Wight, T. N., Schwartz, S. M. (1983) Neovascular responses induced by cultured aortic endothelial cells. J. Cell. Physiol. 114, 302-310
38. Mendenhall, W., Beaver, R. R. (1994) Introduction to Probability and Statistics, 9th Ed, 2.7. The box plot, pp. 91-95, Duxbury Press, Boston
39. Thim, L., Norris, K., Norris, F., Nielsen, P. F., Bjorn, S. E., Christensen, M., Petersen, J. (1993) Purification and characterization of the trefoil peptide human spasmolytic polypeptide (hSP) produced in yeast. FEBS Lett. 318, 345-352
40. Thim, L., Wöldike, H. F., Nielsen, P. F., Christensen, M., Lynch-Devaney, K., Podolsky, D. K. (1995) Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 34, 4757-4764
41. Chadwick, M. P., Westley, B. R., May, F. E. B. (1997) Homodimerization and hetero-oligomerization of the single-domain trefoil protein pNR-2/pS2 through cysteine 58. Biochem. J. 327, 117-123
42. Woodburn, J. R., Morris, C. Q., Kelly, H., Laight, A. (1998) EGF receptor tyrosine kinase inhibitors as anti-cancer agents-preclinical and early clinical profile of ZD1839. First International Conference on Inhibitors of Protein Kinases, Warsaw, September 1998. Cell. Mol. Biol. Lett. 3, 348-349
43. Binétruy-Tournaire, R., Demangel, C., Malavaud, B., Vassy, R., Rouyre, S., Kraemer, M., Plouët, J., Derbin, C., Perret, G., Mazié, J.-C. (2000) Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J. 19, 1525-1533
44. Markowitz, S. D., Molkentin, K., Gerbic, C., Jackson, J., Stellato, T., Willson, J. K. V. (1990) Growth stimulation by coexpression of transforming growth factor-α and epidermal growth factor-receptor in normal and adenomatous human colon epithelium. J. Clin. Invest. 86, 356-362
45. Forgue-Lafitte, M. E., Laburthe, M., Chamblier, M. C., Moody, A. J., Rosselin, G. (1980) Demonstration of specific receptors for EGF-Urogastrone in isolated rat intestinal epithelial cells. FEBS Lett. 114, 243-246
46. Forgue-Lafitte, M. E., Kobari, L., Gespach, C., Chamblier, M. C., Rosselin, G. (1984) Characterization and repartition of epidermal growth factor-urogastrone receptors in gastric glands isolated from young and adult guinea pigs. Biochim. Biophys. Acta 798, 192-198
47. Ciardiello, F., Caputo, R., Bianco, R., Damiano, V., Fontanini, G., Cuccato, S., De Placido, S., Bianco, A. R., Tortora, G. (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin. Cancer Res. 7, 1459-1465
48. Banks, A. S., Davis, S. M., Bates, S. H., Myers, M. G. (2000) Activation of downstream signals by the long form of the leptin receptor. J. Biol. Chem. 275, 14563-14572
49. Williams, C. S., Luongo, C., Radhika, A., Zhang, T., Lamps, L. W., Nanney, L. B., Beauchamp, R. D., DuBois, R. N. (1996) Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterology 111, 1134-1140
50. Eberhart, C. E., Coffey, R. J., Radhika, A., Giardiello, F. M., Ferrenbach, S., DuBois, R. N. (1994) Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 107, 1183-1188
51. Kutchera, W., Jones, D. A., Matsunami, N., Groden, J., McIntyre, T. M., Zimmerman, G. A., White, R. L., Prescott, S. M. (1996) Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA 93, 4816-4820
52. DuBois, R. N., Tsujii, M., Bishop, P., Awad, J. A., Makita, K., Lanahan, A. (1994) Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am. J. Physiol. 266, G822-G827
53. Masunaga, R., Kohno, H., Dhar, D. K., Ohno, S., Shibakita, M., Kinugasa, S., Yoshimura, H., Tachibana, M., Kubota, H., Nagasue, N. (2000) Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer. Res. 6, 4064-4068
54. Williams, C. S., Tsujii, M., Reese, J., Dey, S. K., DuBois, R. N. (2000) Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105, 1589-1594
55. Daniel, T. O., Liu, H., Morrow, J. D., Crews, B. C., Marnett, L. J. (1999) Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 59, 4574-4577
56. Tsujii, M., DuBois, R. N. (1995) Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 83, 493-501
57. Pai, R., Szabo, I. L., Soreghan, B. A., Atay, S., Kawanaka, H., Tarnawski, A. S. (2001) PGE(2) stimulates VEGF expression in endothelial cells via ERK2./JNK1 signaling pathways. Biochem. Biophys. Res. Commun. 286, 923-928
58. 2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy. Nat. Med. 8, 289-293
59. Labayle, D., Fischer, D., Vielh, P., Drouhin, F., Pariente, A., Bories, C., Duhamel, O., Trousset, M., Attali, P. (1991) Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 101,635-639
60. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., Offerhaus, G. J. A. (1993) Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med. 328, 1313-1316
61. Min mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res. 56, 710-714
62. Jones, M. K., Wang, H., Peskar, B. M., Levin, E., Itani, R. M., Sarfeh, I. J., Tarnawski, A. S. (1999) Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5, 1418-1423
63. Liu, Y., Cox, S. R., Morita, T., Kourembanas, S. (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 5′ enhancer. Circ. Res. 77, 638-643
64. Chua, C. C., Hamdy, R. C., Chua, B. H. (1998) Upregulation of vascular endothelial growth factor by angiotensin II in rat heart endothelial cells. Biochim. Biophys. Acta 1401, 187-194
65. Castilla, M. A., Alvarez Arroyo, M. V., Aceituno, E., Aragoncillo, P., Gonzalez-Pacheco, F. R., Texeiro, E., Bragado, R., Caramelo, C. (1999) Disruption of cadherin-related junctions triggers autocrine expression of vascular endothelial growth factor in bovine aortic endothelial cells. Circ. Res. 85, 1132-1138
66. Vega-Diaz, B., Herron, G. S., Michel, S. (2001) An autocrine loop mediates expression of vascular endothelial growth factor in human dermal microvascular endothelial cells. J. Invest. Dermatol. 116, 525-530
67. Cockerill, G. W., Meyer, G., Noack, L., Vadas, M. A., Gamble, J. R. (1994) Characterization of a spontaneously transformed human endothelial cell line. Lab. Invest. 71, 497-509
68. Gluzman-Poltorak, Z., Cohen, T., Herzog, Y., Neufeld, G. (2000) Neuropilin-2 and neuropilin-1 are receptors for the 165-amino acid form of vascular endothelial growth factor (VEGF) and of placenta growth factor-2, but only neuropilin-2 functions as a receptor for the 145-amino acid form of VEGF. J. Biol. Chem. 275, 18040-18045
69. He, Z., Tessier-Lavigne, M. (1997) Neuropilin is a receptor for the axonal chemorepellent Semaphorin III. Cell 90, 739-751
70. Kolodkin, A. L., Levengood, D. V., Rowe, E. G., Tai, Y. T., Giger, R. J., Ginty, D. D. (1997) Neuropilin is a semaphorin III receptor. Cell 90, 753-762
71. Soker, S., Takashima, S., Miao, H. Q., Neufeld, G., Klagsbrun, M. (1998) Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor. Cell 92, 735-745
72. Whitaker, G. B., Limberg, B. J., Rosenbaum, J. S. (2001) Vascular endothelial growth factor receptor-2 and neuropilin-1 form a receptor complex that is responsible for the differential signaling potency of VEGF(165) and VEGF(121). J. Biol. Chem. 276, 25520-25531
73. Attoub, S., Noë, V., Pirola, L., Bruyneel, E., Chastre, E., Mareel, M., Wymann, M. P., Gespach, C. (2000) Leptin promotes invasiveness of kidney and colonic epithelial cells via phosphoinositide 3-kinase-, Rho- and Rac-dependent signaling pathways. FASEB J. 14, 2329-2338
74. Furuta, G. T., Turner, J. R., Taylor, C. T., Hershberg, R. M., Comerford, K., Narravula, S., Podolsky, D. K., Colgan, S. P. (2001) Hypoxia-inducible factor 1-dependent induction of intestinal trefoil factor protects barrier function during hypoxia. J. Exp. Med. 193, 1027-1034
75. Gothié, E., Pouysségur, J. (2002) HIF-1: régulateur central de l'hypoxie. Méd./Sci. 18, 70-78
76. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95, 7987-7992